A player in the healthcare industry
Three industrial sites located in France
Two complementary sites manufacture plasma-derived medicinal products: In Les Ulis for upstream production phases and in Lille, for downstream production process. A manufacturing site in Alès is dedicated to the production of recombinant proteins and monoclonal antibodies by cell culture.
Major, sustained industrial investment in France
In Les Ulis and Lille, our investments in our industrial facilities between
2019 and 2021 will total almost 80 million euros. An industrial investment plan to build a new plant in Arras (France) has been implemented involving €550 M. This investment will enable LFB to step up its production capacity, supporting its international growth and increasing medicines available to patients. LFB expects to create up to 250 jobs by 2024.